Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens

Archives of Neurology

Volumn 69, Issue 9, 2012, Pages 1132-1140

  Orange, Dana ^a,b   Frank, Mayu ^a   Tian, Suyan ^a   Dousmanis, Athanasios ^f   Marmur, Ronen ^g   Buckley, Noreen ^d   Parveen, Salina ^a   Graber, Jerome J ^e   Blachère, Nathalie ^a   Darnell, Robert B ^a,c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f Westmed Medical Group   (United States)

^g Mount Kisco Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ATAXIA; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG INDUCED HEADACHE; DYSARTHRIA; ENCEPHALOMYELITIS; FATIGUE; FEMALE; HEMATOCRIT; HERPETIC STOMATITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MOUTH ABSCESS; NAUSEA; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NEUROPATHY; PLEOCYTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; TREMOR; UREA NITROGEN BLOOD LEVEL; VOMITING; WEAKNESS;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84866141837     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.595     Document Type: Article

References (29)

1. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore). 1992;71(2):59-72.
2. Keime-Guibert F, Graus F, Broët P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999;53(8):1719-1723. (Pubitemid 29530345)
3. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479-482. (Pubitemid 30248748)
4. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(pt 6):1409-1418. (Pubitemid 36644385)
5. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55(5):713-715.
6. Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253(1):16-20. (Pubitemid 43157382)
7. Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55-62. (Pubitemid 38139640)
8. Furneaux HF, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 1990;40(7):1085-1091. (Pubitemid 20213976)
9. Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology. 1994;44(1):140-147. (Pubitemid 24029445)
10. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumorspecific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998;4(11):1321-1324. (Pubitemid 28512116)
11. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47(1):9-17. (Pubitemid 30033645)
12. Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest. 2009;119(7):2042-2051.
13. Darnell RB, Posner JB. Paraneoplastic Syndromes. Oxford, England: Oxford University Press; 2011.
14. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227-2243.
15. Tuosto L, Cundari E, Gilardini Montani MS, Piccolella E. Analysis of susceptibility of mature human T lymphocytes to dexamethasone-induced apoptosis. Eur J Immunol. 1994;24(5):1061-1065. (Pubitemid 24132236)
16. Renoir JM, Mercier-Bodard C, Hoffmann K, et al. Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: a possible role for different heat shock proteinbinding immunophilins in glucocorticosteroid receptor-mediated gene expression. Proc Natl Acad Sci U S A. 1995;92(11):4977-4981.
17. Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59- kilodalton immunophilin with the glucocorticoid receptor complex. Science. 1992;256(5061):1315-1318.
18. Migita K, Eguchi K, Kawabe Y, Origuchi T, Tominaga M, Nagataki S. FK506 potentiates steroid-induced T-cell apoptosis. Transplantation. 1997;64(9):1365-1369. (Pubitemid 27495974)
19. Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem. 1993;39(11, pt 1):2219-2228. (Pubitemid 23333310)
20. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543-1554. (Pubitemid 37255041)
21. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223-243. (Pubitemid 27398022)
22. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection: European FK506 Multicentre Liver Study Group. Lancet. 1994;344(8920):423-428.
23. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation: the U.S. Multicenter FK506 Liver Study Group. N Engl J Med. 1994;331(17):1110-1115.
24. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK 506 multicenter concentration control study: one-year follow-up. Transplant Proc. 1995;27(1):809-811.
25. Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(pt 6):1138-1148. (Pubitemid 32510382)
26. Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249(6):745-753. (Pubitemid 34651757)
27. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 2006;33(3):270-298. (Pubitemid 43849931)
28. Psimaras D, Carpentier AF, Rossi C; PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry. 2010;81(1):42-45.
29. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G; PNS Euronetwork. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330-335.